Oncology

Articles:
169 Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.
http://www.pnas.org/content/114/4/740.abstract

168 A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
http://stm.sciencemag.org/content/9/372/eaag2611

167 Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4232.html

166 Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4252.html

165 Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext

164 Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32455-2/fulltext

163 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32453-9/fulltext

162 T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609279

161 Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611406

160 Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611310

159 TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
http://www.nejm.org/doi/full/10.1056/NEJMoa1605949

158 Palbociclib and Letrozole in Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607303

157 A personalized DC/AML fusion cell vaccine promotes the expansion of leukemia-specific T cells and prolonged remission in patients.
http://stm.sciencemag.org/content/8/368/368ra171.abstract

156 Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609214

155 Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609709

154 Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611299

153 Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602252

152 Mutational signatures associated with tobacco smoking in human cancer.
http://science.sciencemag.org/content/354/6312/618

151 Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607751

150 Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
http://stm.sciencemag.org/content/8/360/360ra135

149 Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1509277

148 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602253

147 Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1606038

146 Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31388-5/fulltext

145 Cord-Blood Transplantation in Patients with Minimal Residual Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602074?query=featured_home

144 Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
http://www.nejm.org/doi/full/10.1056/NEJMoa1515725

143 Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
http://www.nejm.org/doi/full/10.1056/NEJMoa1604700

142 Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00577-8/abstract

141 Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30583-9/abstract

140 Genomic Classification and Prognosis in Acute Myeloid Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516192

139 Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/abstract

138 Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/abstract

137 PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1603702

136 Clinical trial of blood-brain barrier disruption by pulsed ultrasound.
http://stm.sciencemag.org/content/8/343/343re2

135 Toca 511 and Toca FC show promising results in treating recurrent high-grade glioma, and a specific molecular signature correlates with treatment-related survival.
http://stm.sciencemag.org/content/8/341/341ra75.abstract

134 Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00561-4/abstract

133 Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01317-3/abstract

132 Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516282

131 Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice.
http://www.pnas.org/content/113/9/E1306.abstract

130 CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506597

Free Images for Presentation: sunipix SUNIPIX